Mergers & acquisitions
With more than 15 million people in need of anticoagulants around the world, AMAG sees a significant future for ciraparantag.
Bausch Health Companies is acquiring basically all of Synergy Pharmaceuticals’ assets, including all rights to Trulance (plecanatide), dolcanatide and related intellectual property.
Shares of Mallinckrodt PLC are down nearly 2 percent in morning trading after the company announced it will spin off a new company that includes its specialty generics business to shareholders by the second half of 2019.
GlaxoSmithKline plc and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion).
Although it was probably not in serious peril, shareholders of Japan’s Takeda Pharmaceutical voted to approve the acquisition of Dublin’s Shire. The deal is currently valued at $58 billion.
Shareholders raise concern over the fairness of the reverse merger and question potential conflicts of interest of OvaScience’s co-founder.
GlaxoSmithKline announced it will acquire the Tesaro, based in Waltham, Mass., for $5.1 billion. For GSK, the deal marks an increased focus on oncology as it focuses on high growth areas.
Coeptis Pharmaceuticals, Inc. today announced that it has entered into a binding agreement to acquire all outstanding shares of Elto Pharma, Inc.
Elto Pharma is developing eltoprazine, which is in Phase IIb clinical development for Parkinson’s disease levodopa-induced dyskinesias, or Parkinson’s LID.
Roche subsidiary Genentech snaps up Jecure and its portfolio of preclinical NLRP3 inhibitors aimed at serious inflammatory diseases.
PRESS RELEASES